These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 26945158

  • 1. Eicosapentaenoic Acid Inhibits Oxidation of ApoB-containing Lipoprotein Particles of Different Size In Vitro When Administered Alone or in Combination With Atorvastatin Active Metabolite Compared With Other Triglyceride-lowering Agents.
    Mason RP, Sherratt SC, Jacob RF.
    J Cardiovasc Pharmacol; 2016 Jul; 68(1):33-40. PubMed ID: 26945158
    [Abstract] [Full Text] [Related]

  • 2. Atorvastatin active metabolite inhibits oxidative modification of small dense low-density lipoprotein.
    Jacob RF, Walter MF, Self-Medlin Y, Mason RP.
    J Cardiovasc Pharmacol; 2013 Aug; 62(2):160-6. PubMed ID: 23575262
    [Abstract] [Full Text] [Related]

  • 3. Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism.
    Mason RP, Jacob RF.
    Biochim Biophys Acta; 2015 Feb; 1848(2):502-9. PubMed ID: 25449996
    [Abstract] [Full Text] [Related]

  • 4. Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin.
    Mason RP, Dawoud H, Jacob RF, Sherratt SCR, Malinski T.
    Biomed Pharmacother; 2018 Jul; 103():1231-1237. PubMed ID: 29864903
    [Abstract] [Full Text] [Related]

  • 5. Eicosapentaenoic acid inhibits oxidation of high density lipoprotein particles in a manner distinct from docosahexaenoic acid.
    Sherratt SCR, Mason RP.
    Biochem Biophys Res Commun; 2018 Feb 05; 496(2):335-338. PubMed ID: 29331380
    [Abstract] [Full Text] [Related]

  • 6. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation.
    Aviram M, Rosenblat M, Bisgaier CL, Newton RS.
    Atherosclerosis; 1998 Jun 05; 138(2):271-80. PubMed ID: 9690910
    [Abstract] [Full Text] [Related]

  • 7. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
    Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PH, Newton RS, Huff MW.
    Endocrinology; 1999 Nov 05; 140(11):5293-302. PubMed ID: 10537160
    [Abstract] [Full Text] [Related]

  • 8. Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus.
    Ooi EM, Watts GF, Chan DC, Pang J, Tenneti VS, Hamilton SJ, McCormick SP, Marcovina SM, Barrett PH.
    Arterioscler Thromb Vasc Biol; 2015 Dec 05; 35(12):2686-93. PubMed ID: 26515419
    [Abstract] [Full Text] [Related]

  • 9. Lycopene synergistically inhibits LDL oxidation in combination with vitamin E, glabridin, rosmarinic acid, carnosic acid, or garlic.
    Fuhrman B, Volkova N, Rosenblat M, Aviram M.
    Antioxid Redox Signal; 2000 Dec 05; 2(3):491-506. PubMed ID: 11229363
    [Abstract] [Full Text] [Related]

  • 10. Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro.
    Sherratt SCR, Juliano RA, Mason RP.
    Biochim Biophys Acta Biomembr; 2020 Jul 01; 1862(7):183254. PubMed ID: 32135144
    [Abstract] [Full Text] [Related]

  • 11. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia.
    Maki KC, Bays HE, Dicklin MR, Johnson SL, Shabbout M.
    J Clin Lipidol; 2011 Jul 01; 5(6):483-92. PubMed ID: 22108152
    [Abstract] [Full Text] [Related]

  • 12. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
    Yadav R, Liu Y, Kwok S, Hama S, France M, Eatough R, Pemberton P, Schofield J, Siahmansur TJ, Malik R, Ammori BA, Issa B, Younis N, Donn R, Stevens A, Durrington P, Soran H.
    J Am Heart Assoc; 2015 Sep 15; 4(9):e001508. PubMed ID: 26374297
    [Abstract] [Full Text] [Related]

  • 13. Effect of atorvastatin therapy on oxidant-antioxidant status and atherosclerotic plaque formation.
    Sezer ED, Sozmen EY, Nart D, Onat T.
    Vasc Health Risk Manag; 2011 Sep 15; 7():333-43. PubMed ID: 21731885
    [Abstract] [Full Text] [Related]

  • 14. Eicosapentaenoic acid improves endothelial function in hypertriglyceridemic subjects despite increased lipid oxidizability.
    Okumura T, Fujioka Y, Morimoto S, Tsuboi S, Masai M, Tsujino T, Ohyanagi M, Iwasaki T.
    Am J Med Sci; 2002 Nov 15; 324(5):247-53. PubMed ID: 12449445
    [Abstract] [Full Text] [Related]

  • 15. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.
    Millar JS, Brousseau ME, Diffenderfer MR, Barrett PH, Welty FK, Faruqi A, Wolfe ML, Nartsupha C, Digenio AG, Mancuso JP, Dolnikowski GG, Schaefer EJ, Rader DJ.
    Arterioscler Thromb Vasc Biol; 2006 Jun 15; 26(6):1350-6. PubMed ID: 16574893
    [Abstract] [Full Text] [Related]

  • 16. Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity.
    Chan DC, Watts GF, Barrett PH, Mori TA, Beilin LJ, Redgrave TG.
    J Clin Endocrinol Metab; 2002 May 15; 87(5):2283-9. PubMed ID: 11994377
    [Abstract] [Full Text] [Related]

  • 17. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.
    Krauss RM, Pinto CA, Liu Y, Johnson-Levonas AO, Dansky HM.
    J Clin Lipidol; 2015 May 15; 9(1):93-102. PubMed ID: 25670366
    [Abstract] [Full Text] [Related]

  • 18. Atorvastatin might inhibit insulin resistance induced by insulin through the triglyceride-lowering role of Apolipoprotein AV.
    Zhao W, Zhao SP.
    Eur Rev Med Pharmacol Sci; 2015 Oct 15; 19(20):3895-903. PubMed ID: 26531276
    [Abstract] [Full Text] [Related]

  • 19. Eicosapentaenoic acid administration attenuates the pro-inflammatory properties of VLDL by decreasing its susceptibility to lipoprotein lipase in macrophages.
    Jinno Y, Nakakuki M, Kawano H, Notsu T, Mizuguchi K, Imada K.
    Atherosclerosis; 2011 Dec 15; 219(2):566-72. PubMed ID: 22018640
    [Abstract] [Full Text] [Related]

  • 20. Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins.
    Lankin VZ, Tikhaze AK, Kukharchuk VV, Konovalova GG, Pisarenko OI, Kaminnyi AI, Shumaev KB, Belenkov YN.
    Mol Cell Biochem; 2003 Jul 15; 249(1-2):129-40. PubMed ID: 12956408
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.